News

MHRA grants approval of Phase 1 clinical trial, expected to start in H2 2022 Alderley Park, Cheshire, U.K – Infex Therapeutics, a leader in critical-priority infectious diseases, is pleased to announce it has received approval from the...

Maxwellia has appointed Ian Adamson as strategic advisor to shape the next phase of pharmacy medicine launches – a process which involves identifying and converting suitable prescription only medicines into versions people can choose to...

28 April 2022 - Manchester, UK.  The GM&C Life Sciences Fund, managed by Catapult Ventures, has announced a 3.3x cash return (115.6% IRR), from its exit of Panthera Biopartners Ltd. The exit comes as part of a £10m further funding...

MANCHESTER, England, April 22, 2022 /PRNewswire/ -- Following the reclassification of the daily progestogen-only pill earlier this year, Maxwellia made history by launching Lovima® (desogestrel 75mcg) one of the first oral...

Proveca Ltd is excited to announce a significant agreement outside Europe with Biopas Laboratories based in Colombia.  Biopas will commercialise and distribute Sialanar® exclusively throughout Spanish speaking territories in South Am...